Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity
Self archived versionfinal draft
MetadataShow full item record
CitationDufva, O. Koski, J. Maliniemi, P. Ianevski, A. Klievink, J. Leitner, J. Pölönen, P. Hohtari, H. Saeed, K. Hannunen, T. Ellonen, P. Steinberger, P. Kankainen, M. Aittokallio, T. Keränen, MAI. Korhonen, M. Mustjoki, S. (2020). Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity. Blood, 135 (9) , 597-609. 10.1182/blood.2019002121.
Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and refractory B-cell malignancies, but resistance and relapses still occur. Better understanding of mechanisms influencing CAR T-cell cytotoxicity and the potential for modulation using small-molecule drugs could improve current immunotherapies. Here, we systematically investigated druggable mechanisms of CAR T-cell cytotoxicity using >500 small-molecule drugs and genome-scale CRISPR-Cas9 loss-of-function screens. We identified several tyrosine kinase inhibitors that inhibit CAR T-cell cytotoxicity by impairing T-cell signaling transcriptional activity. In contrast, the apoptotic modulator drugs SMAC mimetics sensitized B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma cells to anti-CD19 CAR T cells. CRISPR screens identified death receptor signaling through FADD and TNFRSF10B (TRAIL-R2) as a key mediator of CAR T-cell cytotoxicity and elucidated the RIPK1-dependent mechanism of sensitization by SMAC mimetics. Death receptor expression varied across genetic subtypes of B-cell malignancies, suggesting a link between mechanisms of CAR T-cell cytotoxicity and cancer genetics. These results implicate death receptor signaling as an important mediator of cancer cell sensitivity to CAR T-cell cytotoxicity, with potential for pharmacological targeting to enhance cancer immunotherapy. The screening data provide a resource of immunomodulatory properties of cancer drugs and genetic mechanisms influencing CAR T-cell cytotoxicity.
Subjectsburkitt's lymphoma crispr cytotoxicity death domain receptors t-lymphocytes signal transduction screening cancer leukemia b-cell acute cd19 antigens
Link to the original itemhttp://dx.doi.org/10.1182/blood.2019002121
PublisherAmerican Society of Hematology
- Terveystieteiden tiedekunta